Business
Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream
Data presented at Revolutionizing Atopic Dermatitis (RAD) ConferenceVehicle tested was comparable to the moisturizing cream based on primary endpoint of
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Data presented at Revolutionizing Atopic Dermatitis (RAD) ConferenceVehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from baseline at Day 15Data provide additional support for ongoing studies of investigational product roflumilast cream in atopic dermatitis WESTLAKE VILLAGE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced data suggesting that Arcutis’ proprietary cream vehicle had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema. The data from the two groups were similar across patient and healthcare provider assessments of tolerability and aesthetic improvement. Atopic dermatitis and other forms of eczema have underlying skin barrier defects, which can be further exacerbated by topical medications that harm the skin barrier. Arcutis designed its cream vehicle with both 50% water content and an ultra-mild emulsifier at PH of the skin, as well as excluding propylene glycol, polyethylene glycol, ethanol, or fragrance. “In this study, both the Arcutis cream vehicle and a dermatologist-recommended, ceramide-containing moisturizing cream were well received by patients, with patients reporting improvements in dryness, redness, irritation and other skin characteristics, as well as positive feedback on the aesthetic properties of the two creams. As a clinician, I was impressed by the moisturizing properties of the Arcutis vehicle,” said Zoe Diana Draelos, MD, President and Principal Investigator, Dermatology Consulting Services, PLLC. Data from the 40-patient, single-site, randomized, double-blinded intraindividual study were presented at the annual RAD Conference. Patients with mild asteatotic eczema applied either roflumilast vehicle cream (without the active ingredient roflumilast) or the ceramide-containing moisturizer to their lower legs (randomized by leg with each subject receiving the ceramide-containing moisturizer and the Arcutis cream vehicle on opposite legs). There was no statistically significant change from baseline in TEWL at Day 15 with either preparation, suggesting that no skin barrier...